ABT-199: A Potent and Selective Bcl-2 Inhibitor for Pharmaceutical Advancement
Explore the therapeutic potential of ABT-199, a highly selective Bcl-2 inhibitor crucial for advancements in oncology and pharmaceutical research. Discover its mechanism, applications, and reliable sourcing options from leading manufacturers.
Get a Quote & SampleUnlocking Therapeutic Potential with ABT-199
ABT-199 (CAS 1257044-40-8)
ABT-199, also known as Venetoclax, is a cutting-edge, orally bioavailable BH3 mimetic that exhibits exceptional selectivity for Bcl-2 inhibition. As a key pharmaceutical intermediate, it plays a vital role in the development of novel cancer therapies. We, as a trusted supplier in China, offer high-purity ABT-199 for your critical research and development needs, ensuring consistent quality and competitive pricing.
- Discover the mechanism of ABT-199 as a selective Bcl-2 inhibitor, crucial for understanding its therapeutic impact.
- Learn about ABT-199's role in inducing apoptosis, a fundamental process in eliminating cancerous cells.
- Investigate ABT-199's application in treating Chronic Lymphocytic Leukemia (CLL) and other hematological malignancies.
- Source high-quality ABT-199 from reliable manufacturers and suppliers for your pharmaceutical projects.
Advantages of Sourcing ABT-199
High Selectivity and Potency
ABT-199 offers subnanomolar affinity for Bcl-2, making it a highly selective and potent inhibitor. This specificity is key for targeted cancer therapies and minimizes off-target effects, a crucial consideration for pharmaceutical manufacturers.
Therapeutic Efficacy in Oncology
Demonstrated efficacy in preclinical and clinical studies for treating chronic lymphocytic leukemia (CLL) and other BCL-2 dependent cancers makes ABT-199 a valuable pharmaceutical intermediate for drug developers seeking effective treatment options. Buy ABT-199 to advance your research.
Reliable Supply Chain and Quality Assurance
As a leading manufacturer and supplier of ABT-199 in China, we ensure consistent product quality, reliable supply, and competitive pricing. Our commitment to quality control makes us the ideal partner for your pharmaceutical procurement needs.
Key Applications of ABT-199
Oncology Drug Development
ABT-199 serves as a critical API in the development of novel oncology drugs, targeting BCL-2 overexpression in various cancers. Purchase ABT-199 for your targeted therapy research.
Chronic Lymphocytic Leukemia (CLL) Research
Its proven efficacy in treating CLL makes ABT-199 a compound of significant interest for researchers and pharmaceutical companies focused on hematological oncology treatments.
Bcl-2 Mediated Disease Research
Beyond leukemia, ABT-199 is utilized to investigate and develop treatments for other diseases where the BCL-2 protein plays a critical role in cell survival and resistance to apoptosis.
Biochemical Research Tool
As a well-characterized inhibitor, ABT-199 is an indispensable tool for academic and industrial laboratories studying cell death pathways and molecular mechanisms of cancer.